Conditions such as elevated low-density lipoprotein cholesterol (LDL-C), high triglycerides, elevated lipoprotein(a) [Lp(a)], homozygous familial hypercholesterolemia (HoFH), lipodystrophy syndromes, and pediatric dyslipidemias require timely diagnosis and individualized treatment. The complexity of these disorders—many of which are quite rare—requires clinicians to possess a nuanced understanding of their pathophysiology and presentation. Fortunately, the treatment landscape for lipid disorders is rapidly expanding to include a range of recently approved and emerging therapeutic options. The Lipid Legends podcast series highlights accomplished lipid specialists to highlight clinical challenges and provide actionable insights into disorders, including elevated LDL-C, elevated Lp(a), lipodystrophy, pediatric lipid disorders, hypertriglyceridemia (HTG), and HoHF.
This activity is supported by educational funding provided by Amgen; Arrowhead Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
This activity is supported by educational funding provided by Amgen; Arrowhead Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
This activity is supported by educational funding provided by Amgen; Arrowhead Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
This activity is supported by educational funding provided by Amgen; Arrowhead Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
This activity is supported by educational funding provided by Amgen; Arrowhead Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
This activity is supported by educational funding provided by Amgen; Arrowhead Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.
